Last reviewed · How we verify
Phenozolone (FENOZOLONE)
Phenozolone (generic name: FENOZOLONE) is a fenozolone drug. It is currently in Phase 2 development.
Phenozolone works by interacting with a specific target in the body, but its exact mechanism is currently unknown.
Phenozolone (FENOZOLONE) is a small molecule drug in the fenozolone class, but its target and mechanism of action are unknown. Its commercial status and approved indications are also unclear. As a result, key safety considerations and pharmacokinetic properties such as half-life and bioavailability are not well established. Further research is needed to fully understand this compound. Its ownership and patent status are also unknown.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FENOZOLONE |
|---|---|
| Drug class | fenozolone |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like locks, and the key to unlocking them is a specific target. Phenozolone is like a key that fits into this lock, but we don't know what the lock looks like or how it works yet. This means we can't be sure how it will affect the body or what side effects it might cause.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phenozolone CI brief — competitive landscape report
- Phenozolone updates RSS · CI watch RSS
Frequently asked questions about Phenozolone
What is Phenozolone?
How does Phenozolone work?
What is the generic name of Phenozolone?
What drug class is Phenozolone in?
What development phase is Phenozolone in?
Related
- Drug class: All fenozolone drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing